MEDIPOST Co. Ltd
MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthrit… Read more
MEDIPOST Co. Ltd (078160) - Total Liabilities
Latest total liabilities as of September 2025: ₩109.40 Billion KRW
Based on the latest financial reports, MEDIPOST Co. Ltd (078160) has total liabilities worth ₩109.40 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
MEDIPOST Co. Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how MEDIPOST Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
MEDIPOST Co. Ltd Competitors by Total Liabilities
The table below lists competitors of MEDIPOST Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kepler Weber S.A
SA:KEPL3
|
Brazil | R$825.13 Million |
|
DRB - Hicom Bhd
KLSE:1619
|
Malaysia | RM53.85 Billion |
|
FB Bancorp, Inc. Common Stock
NASDAQ:FBLA
|
USA | $940.96 Million |
|
Heartland Banccorp
OTCQX:HLAN
|
USA | $1.76 Billion |
|
Hunan Zhenghong Science and Technology Develop Co Ltd
SHE:000702
|
China | CN¥212.28 Million |
|
Evans Bancorp Inc
NYSE MKT:EVBN
|
USA | $2.00 Billion |
|
D&L Industries Inc
PINK:DALQF
|
USA | $30.12 Billion |
|
Sino-Argi Leading Biosciences
SHG:603970
|
China | CN¥4.85 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down MEDIPOST Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MEDIPOST Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MEDIPOST Co. Ltd (2011–2024)
The table below shows the annual total liabilities of MEDIPOST Co. Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩161.69 Billion | +19.12% |
| 2023-12-31 | ₩135.74 Billion | -37.68% |
| 2022-12-31 | ₩217.82 Billion | +130.22% |
| 2021-12-31 | ₩94.61 Billion | -8.38% |
| 2020-12-31 | ₩103.27 Billion | +1.11% |
| 2019-12-31 | ₩102.13 Billion | +108.69% |
| 2018-12-31 | ₩48.94 Billion | +21.75% |
| 2017-12-31 | ₩40.20 Billion | +11.81% |
| 2016-12-31 | ₩35.95 Billion | -1.36% |
| 2015-12-31 | ₩36.45 Billion | -46.89% |
| 2014-12-31 | ₩68.63 Billion | +142.10% |
| 2013-12-31 | ₩28.35 Billion | +40.26% |
| 2012-12-31 | ₩20.21 Billion | +20.64% |
| 2011-12-31 | ₩16.75 Billion | -- |